Ascletis Pharma (HKG:1672) will present the study results of its obesity products ASC30 tablets and injection, as well as the combination of ASC31 and ASC47 at ObesityWeek 2025 in Atlanta, Georgia, a Monday Hong Kong bourse filing said.
The poster presentations will take place at the international conference for obesity researchers and clinicians on Nov. 4.